| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
7-Methoxyrosmanol targets the cAMP signaling pathway, specifically suppressing the cAMP responsiveness of PEPCK (phosphoenolpyruvate carboxykinase) and G6Pase (glucose-6-phosphatase) gene promoters. These enzymes are key regulators of gluconeogenesis. By suppressing their promoters, 7-methoxyrosmanol reduces the expression of these enzymes, leading to decreased hepatic glucose production. This mechanism contributes to its antihyperglycemic activity.
|
|---|---|
| ln Vitro |
In vitro, 7-methoxyrosmanol effectively suppresses forskolin (FSK)-induced luciferase expression under the control of the CRE (cAMP response element), PEPCK-C, and G6Pase gene promoters. This activity indicates that the compound inhibits cAMP-responsive gene expression. It may contribute to its antihyperglycemic activity by reducing gluconeogenic gene expression. The compound is a phenolic diterpene isolated from rosemary.
|
| ln Vivo |
7-Methoxyrosmanol is not a pharmacologically approved drug and does not have established in vivo therapeutic activity. It has been studied for its potential antihyperglycemic effects through the suppression of gluconeogenic gene promoters. The compound may have applications in the treatment of diabetes and metabolic disorders, but these have not been validated in clinical settings. It is a research compound used to study cAMP signaling and gluconeogenesis.
|
| Enzyme Assay |
In vitro assays for 7-methoxyrosmanol typically involve reporter gene assays to assess its effects on cAMP-responsive gene expression. A standard protocol involves transfecting cells with luciferase reporter constructs containing the CRE, PEPCK-C, or G6Pase promoters. Cells are treated with varying concentrations of 7-methoxyrosmanol (typically 1-100 µM) in the presence of forskolin to stimulate cAMP production. Luciferase activity is measured after 24-48 hours. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
In vitro cell culture experiments with 7-methoxyrosmanol typically involve hepatocytes or other cell lines expressing gluconeogenic genes. Cells are cultured in appropriate media and treated with the compound at concentrations ranging from 1-100 µM for 24-48 hours. Gene expression of PEPCK and G6Pase is measured by qPCR or reporter gene assays. Cell viability is assessed using MTT assays to ensure that observed effects are not due to cytotoxicity.
|
| Animal Protocol |
In vivo animal studies with 7-methoxyrosmanol are not well documented, as it is primarily a research compound. If conducted, typical protocols for antihyperglycemic studies would involve administering the compound to diabetic or obese mouse models. Blood glucose levels would be monitored over time, and liver tissue would be collected for analysis of gluconeogenic gene expression. However, such studies are not standard for this compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 7-methoxyrosmanol are not characterized, as it is not a drug substance. Based on its physicochemical properties (molecular weight 360.44), the compound would be expected to have moderate lipophilicity. However, the compound is not intended for human exposure and has not been evaluated in formal pharmacokinetic studies.
|
| Toxicity/Toxicokinetics |
7-Methoxyrosmanol may cause skin and eye irritation. Standard laboratory safety precautions should be followed when handling this compound, including the use of gloves, safety glasses, and working in a fume hood. The compound should be stored in a cool, dry place away from light and moisture. No acute toxicity data are available. The compound is not intended for drug, household, or other uses.
|
| References | |
| Additional Infomation |
7-O-methylrosmannol has been reported to have been found in sage, urban sage, and other organisms with available data.
7-Methoxyrosmanol is a phenolic diterpene isolated from rosemary (Rosmarinus officinalis). It suppresses the cAMP responsiveness of PEPCK and G6Pase promoters, which may contribute to its antihyperglycemic activity. The compound is used in research on diabetes and metabolic disorders. It has not undergone clinical trials and is not approved as a pharmaceutical. |
| Molecular Formula |
C21H28O5
|
|---|---|
| Molecular Weight |
360.44
|
| Exact Mass |
360.193
|
| CAS # |
113085-62-4
|
| PubChem CID |
23243692
|
| Appearance |
White to off-white solid
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
542.3±50.0 °C at 760 mmHg
|
| Flash Point |
189.7±23.6 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.595
|
| LogP |
3.03
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
26
|
| Complexity |
587
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC(C)C1=CC2=C(C(=C1O)O)[C@@]34CCCC(C)(C)[C@@H]3[C@@H]([C@H]2OC)OC4=O
|
| InChi Key |
XNPVHIQPSAZTLC-NYUBLWNDSA-N
|
| InChi Code |
InChI=1S/C21H28O5/c1-10(2)11-9-12-13(15(23)14(11)22)21-8-6-7-20(3,4)18(21)17(16(12)25-5)26-19(21)24/h9-10,16-18,22-23H,6-8H2,1-5H3/t16-,17+,18-,21-/m0/s1
|
| Chemical Name |
(1R,8S,9S,10S)-3,4-dihydroxy-8-methoxy-11,11-dimethyl-5-propan-2-yl-16-oxatetracyclo[7.5.2.01,10.02,7]hexadeca-2,4,6-trien-15-one
|
| Synonyms |
7-O-Methoxyrosmanol; 7-Methoxyrosmanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (277.44 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (6.94 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.94 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7744 mL | 13.8719 mL | 27.7439 mL | |
| 5 mM | 0.5549 mL | 2.7744 mL | 5.5488 mL | |
| 10 mM | 0.2774 mL | 1.3872 mL | 2.7744 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
